NIH: Peer-Reviewed Data Shows Remdesivir for COVID-19 Improves Time to Recovery
May 25, 2020
May 25, 2020
WASHINGTON, May 25 -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release on May 22:
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published in the New England Journal of Medicine.
The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy a . . .
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published in the New England Journal of Medicine.
The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy a . . .